Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Response to Letter by Lippi and Mattiuzzi

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  4. Diagnosis and management of migraine in ten steps

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Hypersensitivity to calcitonin gene-related peptide in chronic migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Headache is a frequent symptom following COVID-19 immunization with a typical onset within days post-vaccination. Cases of cerebral venous thrombosis (CVT) have been reported in adenovirus vector-based COVID-19 vaccine recipients.

FINDINGS: We reviewed all vaccine related CVT published cases by April 30, 2021. We assessed demographic, clinical variables and the interval between the vaccination and onset of headache. We assessed whether the presence of headache was associated with higher probability of death or intracranial hemorrhage. We identified 77 cases of CVT after COVID-19 vaccination. Patients' age was below 60 years in 74/77 (95.8%) cases and 61/68 (89.7%) were women. Headache was described in 38/77 (49.4%) cases, and in 35/38 (92.1%) was associated with other symptoms. Multiple organ thrombosis was reported in 19/77 (24.7%) cases, intracranial hemorrhage in 33/77 (42.9%) cases and 19/77 (24.7%) patients died. The median time between vaccination and CVT-related headache onset was 8 (interquartile range 7.0-9.7) days. The presence of headache was associated with a higher odd of intracranial hemorrhage (OR 7.4; 95% CI: 2.7-20.8, p < 0.001), but not with death (OR: 0.51, 95% CI: 0.18-1.47, p = 0.213).

CONCLUSION: Delayed onset of headache following an adenovirus vector-based COVID-19 vaccine is associated with development of CVT. Patients with new-onset headache, 1 week after vaccination with an adenovirus vector-based vaccine, should receive a thorough clinical evaluation and CVT must be ruled out.

OriginalsprogEngelsk
Artikelnummer108
TidsskriftJournal of Headache and Pain
Vol/bind22
Udgave nummer1
Sider (fra-til)108
ISSN1129-2377
DOI
StatusUdgivet - 2021

Bibliografisk note

© 2021. The Author(s).

ID: 67850837